Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Harley Street

3 May 2016 09:01

RNS Number : 0126X
Advanced Oncotherapy PLC
03 May 2016
 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Update on Harley Street

 

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, notes that a number of shareholders have raised concerns that a planning application submitted by Howard de Walden Estates Limited for 141-143 Harley Street was withdrawn in January 2016 and that this will have an impact on the Company's progress.

 

Howard de Walden Estates and Advanced Oncotherapy have confirmed that the withdrawn planning application was for 'use swap' purposes only and did not involve any works to the building which are part of creating the Proton Beam Therapy Facility.

 

The application was withdrawn as the area of the facility had grown in size, as referenced in the update provided on 28 July 2015, and since the original 50 year lease agreement was signed with Howard de Walden Estates in January 2015, the available space for the centre has increased by approximately 50% allowing for an additional treatment room and additional imaging facilities.

 

Howard de Walden Estates are satisfied that progress for the site remains on track. The total cost of the redevelopment is being borne by Howard de Walden Estates.

 

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Michael Sinclair, Chief Executive Office

Tel: +44 20 3617 8728

Nicolas Serandour, Chief Operating and Financial Officer

 

 

 

Stockdale Securities (Nomad & Joint Broker)

 

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

 

 

Beaufort Securities (Joint Broker)

 

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

    

 

 

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers. In October 2015 the Company signed a joint venture agreement with CircleHealth to operate the Company's proton beam cancer therapy centre in Harley Street.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSUSWDFMSEII
Date   Source Headline
4th Jul 20189:00 amRNSPrice Monitoring Extension
2nd Jul 20187:00 amRNSDirectorate Changes
27th Jun 20187:00 amRNSFinal Results
31st May 20187:00 amRNSUpdate on financing
29th May 20187:00 amRNSTechnological update
11th May 20184:35 pmRNSPrice Monitoring Extension
11th May 20187:00 amRNSUpdate on Distribution Agreement Payment
8th May 20187:00 amRNSUK assembly and testing site agreement
26th Apr 20181:50 pmRNSGPSL Research on Advanced Oncotherapy Plc
5th Apr 20187:00 amRNSHolding(s) in Company
3rd Apr 20189:43 amRNSUpdate on Distribution Agreement
12th Mar 20187:15 amRNSHardman & Co Research: Confidence greatly boosted
23rd Feb 20184:05 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSCompletion of the Subscription Agreement
23rd Jan 201811:48 amRNSResult of Meeting
12th Jan 20187:00 amRNSDirector dealing
28th Dec 20177:01 amRNSNotice of GM
28th Dec 20177:00 amRNSTechnological update
22nd Dec 201711:24 amRNSHolding(s) in Company
13th Dec 20174:25 pmRNSHolding(s) in Company
11th Dec 20172:02 pmRNSHardman Res.: Distribution deal & capital increase
7th Dec 20177:00 amRNSDistribution agreement and Equity Investments
29th Sep 20177:00 amRNSHalf-year Report
4th Sep 20177:00 amRNSTechnological update
1st Aug 20177:00 amRNSDirector Dealing
31st Jul 20177:00 amRNSTechnological milestones update - CCL units
19th Jul 20173:56 pmRNSResult of AGM
19th Jul 201710:16 amRNSFinancing facility by significant shareholders
5th Jul 20177:00 amRNSVideo and update on progress at Harley Street
26th Jun 20177:00 amRNSFinal Results
21st Jun 20177:00 amRNSConversion of Convertible Loan Notes
14th Jun 20177:00 amRNSAppointment of Senior VP of Medical Physics
13th Jun 20177:00 amRNSAdditional financing agreement and new appointment
12th Jun 20177:00 amRNSTechnological milestones update
5th Jun 20172:45 pmRNSUpdate on Bracknor financing
31st May 20174:41 pmRNSHolding(s) in Company
30th May 20177:00 amRNSHarley Street construction update
26th May 20176:23 pmRNSConversion of Convertible Loan Notes
26th May 20177:00 amRNSUpdate on Bracknor financing
24th May 20177:13 amRNSConversion of convertible loan notes
23rd May 201712:01 pmRNSHolding(s) in Company
18th May 20177:31 amRNSConversion of convertible loan notes
16th May 20179:02 amRNSConversion of loan notes
15th May 20171:01 pmRNSDirector Dealing
11th May 20177:00 amRNSDirector Dealing
8th May 20177:00 amRNSIssue of Equity & Director Shareholding
4th May 20177:05 amRNSHolding(s) in Company
3rd May 20171:29 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSUpdate on Bracknor financing
26th Apr 201711:18 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.